Estrogen receptor-α (ER) targeted therapies are routinely used to treat breast cancer. affect EGFR expression. Cycloheximide abolished the ability of fulv to activate EGFR suggesting autocrine production of Almorexant EGFR ligands might be responsible for fulvestrant induced EGFR signaling. qRT-PCR results showed fulv differentially regulated EGFR ligands; HB-EGF mRNA was increased while amphiregulin (AREG) and […]